Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus Gemcitabine in Pancreatic Cancer with Pain
NCT03766295Phase 3Completed
- Sponsor
- AB Science
- Start
- Jul 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in pancreatic ductal adenocarcinoma (PDAC) comparing Masitinib & gemcitabine with Placebo & gemcitabine (2 arms). Primary endpoint: Overall Survival at 60 months. Started Jul 2014; status: completed.
02
Drugs
masitinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03766295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766295.